EFM
E Fund Management Portfolio holdings
AUM
$2.1B
This Quarter Return
+14.76%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$2.1B
AUM Growth
+$2.1B
(+0.21%)
Cap. Flow
-$186M
Cap. Flow
% of AUM
-8.85%
Top 10 Holdings %
Top 10 Hldgs %
51.83%
Holding
429
New
31
Increased
85
Reduced
265
Closed
35
Top Buys
| 1 |
abrdn Physical Gold Shares ETF
SGOL
|
$20M |
| 2 |
iShares Gold Trust
IAU
|
$19.8M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
$19.6M |
| 4 |
SPDR Gold Trust
GLD
|
$19.6M |
| 5 |
Invesco DB Oil Fund
DBO
|
$11M |
Top Sells
| 1 |
KE Holdings
BEKE
|
$70.4M |
| 2 |
Futu Holdings
FUTU
|
$37.4M |
| 3 |
Apple
AAPL
|
$18.8M |
| 4 |
Microsoft
MSFT
|
$13.6M |
| 5 |
Applied Materials
AMAT
|
$11.3M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Consumer Discretionary | 23.94% |
| 3 | Communication Services | 11.36% |
| 4 | Healthcare | 5.11% |
| 5 | Financials | 3.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Nike
NKE
$114B
| $217K | 0.01% |
+3,061
| New | +$217K |
|
352
Mirum Pharmaceuticals
MIRM
$3.71B
| $211K | 0.01% |
4,143
-704
| -15% | -$35.8K |
|
353
Arthur J. Gallagher & Co
AJG
$77.6B
| $209K | 0.01% |
654
-149
| -19% | -$47.7K |
|
354
MSCI
MSCI
$43.9B
| $209K | 0.01% |
363
-2,739
| -88% | -$1.58M |
|
355
3M
MMM
$82.8B
| $208K | 0.01% |
1,367
+2
| +0.1% | +$304 |
|
356
Waste Management
WM
$91.2B
| $206K | 0.01% |
900
-22
| -2% | -$5.03K |
|
357
China Yuchai International
CYD
$1.25B
| $206K | 0.01% |
+8,613
| New | +$206K |
|
358
Sherwin-Williams
SHW
$91.2B
| $204K | 0.01% |
595
-121
| -17% | -$41.5K |
|
359
Apogee Therapeutics
APGE
$2.17B
| $204K | 0.01% |
+4,700
| New | +$204K |
|
360
Travere Therapeutics
TVTX
$1.56B
| $204K | 0.01% |
13,789
+236
| +2% | +$3.49K |
|
361
Equinix
EQIX
$76.9B
| $202K | 0.01% |
254
-456
| -64% | -$363K |
|
362
Recursion Pharmaceuticals
RXRX
$2.04B
| $201K | 0.01% |
39,653
-16,272
| -29% | -$82.3K |
|
363
Denali Therapeutics
DNLI
$2.23B
| $190K | 0.01% |
13,612
+1,543
| +13% | +$21.6K |
|
364
Biohaven
BHVN
$1.63B
| $190K | 0.01% |
13,492
+2,307
| +21% | +$32.6K |
|
365
Immunovant
IMVT
$2.56B
| $190K | 0.01% |
11,854
-1,121
| -9% | -$17.9K |
|
366
Dynavax Technologies
DVAX
$1.19B
| $180K | 0.01% |
18,113
+2,752
| +18% | +$27.3K |
|
367
Novavax
NVAX
$1.21B
| $178K | 0.01% |
28,280
+2,326
| +9% | +$14.7K |
|
368
Ardelyx
ARDX
$1.53B
| $157K | 0.01% |
40,023
+3,255
| +9% | +$12.8K |
|
369
Intellia Therapeutics
NTLA
$1.22B
| $135K | 0.01% |
14,339
-2,492
| -15% | -$23.4K |
|
370
89bio
ETNB
$1.34B
| $134K | 0.01% |
13,622
+795
| +6% | +$7.81K |
|
371
Syndax Pharmaceuticals
SNDX
$1.41B
| $131K | 0.01% |
14,033
-1,998
| -12% | -$18.7K |
|
372
Geron
GERN
$893M
| $130K | 0.01% |
92,238
+9,849
| +12% | +$13.9K |
|
373
Dyne Therapeutics
DYN
$1.92B
| $117K | 0.01% |
12,274
-1,497
| -11% | -$14.3K |
|
374
Ford
F
$46.8B
| $111K | 0.01% |
10,208
| – | – |
|
375
Akebia Therapeutics
AKBA
$833M
| $103K | ﹤0.01% |
28,273
+8,962
| +46% | +$32.6K |
|